Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 4:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 4
1 (50.0%)Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein
Phase 4
Suspended
- Conditions
- Fluorescein Angiography
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Kresge Eye Institute
- Target Recruit Count
- 79
- Registration Number
- NCT03244982
- Locations
- 🇺🇸
Kresge Eye Institute, Detroit, Michigan, United States
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- Kresge Eye Institute
- Registration Number
- NCT00618644
- Locations
- 🇺🇸
Kresge Eye Institute, Detroit, Michigan, United States
News
No news found